Quality of life analyses from the randomized, open-label, phase III PointBreak study of pemetrexed-carboplatin-bevacizumab followed by maintenance pemetrexed-bevacizumab versus paclitaxel-carboplatin-bevacizumab followed by maintenance bevacizumab in patients with stage IIIB or IV nonsquamous non-small-cell lung cancer.

Quality of life analyses from the randomized, open-label, phase III PointBreak study of pemetrexed-carboplatin-bevacizumab followed by maintenance pemetrexed-bevacizumab versus paclitaxel-carboplatin-bevacizumab followed by maintenance bevacizumab in patients with stage IIIB or IV nonsquamous non-small-cell lung cancer. J Thorac Oncol. 2015 Feb; 10(2):353-9.

View in: PubMed

subject areas

Antibodies, Monoclonal, Humanized
Antineoplastic Combined Chemotherapy Protocols
Bevacizumab
Carboplatin
Carcinoma, Non-Small-Cell Lung
Drug Administration Schedule
Female
Glutamates
Guanine
Humans
Lung Neoplasms
Male
Neoplasm Staging
Paclitaxel
Pemetrexed
Quality of Life
Treatment Outcome

authors with profiles

Philip Bonomi